Precision Medicine in Oncology®

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

Mark B. Stoopler, MD, discusses ongoing developments in immunotherapy and his vision for the future of non-small cell lung cancer treatment.

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

The so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

It is imperative that surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer, given a shortage of available genetic counselors.

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

Dr. Elizabeth Swisher discusses biomarkers for PARP inhibitors and the evolving role of these agents in ovarian cancer.

The PARP inhibitor olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Two novel imaging agents and 6 clinical assays for use in cancer care gained the FDA's approval in 2016, marking advances in the diagnostic field.